repaglinide glp 1 GLP-1 Receptor Agonists: The New Wave in Diabetes Management Oral and Injectable (Non-Insulin) Pharmacological

This contrasts with the typical profile of liraglutide and may relate to the specific dosing schedule or model variability 15,16

OATP1B1 exhibits the broadest substrate specificity, while other subtypes display more selective affinities

This study underscores the importance of exploring new therapeutic avenues for PCa, particularly for patients with metabolic syndrome and diabetes

Slowing kidney decline in the SURPASS-CVOT trial In patients with high or very high risk chronic kidney disease enrolled in SURPASS-CVOT, tirzepatide dramatically slowed the rate of kidney function decline compared to dulaglutide

The reduction of mMASI was 25% and 76%, respectively [66]